Drug Type Small molecule drug |
Synonyms HMPL 004, HMPL-004 |
Mechanism IL-1β modulators(Interleukin-1 beta modulators), IL-6 receptor family antagonists, NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 3 | US | 01 Mar 2013 | |
Crohn Disease | Phase 2 | - | 01 Apr 2006 | |
Systemic Lupus Erythematosus | Preclinical | - | - |
Phase 2 | 224 | Placebo | dqtgovqtxa(ohxgeombbn) = vwryvlsbsf emizimothd (nuvggfojgn, zcogfayare - zmaaoujtds) View more | - | 22 Jul 2020 | ||
Phase 3 | 66 | (HMPL-004 1800 mg/Day) | mpiqhislad(ssvzvsgqfo) = bjuflrwrgo ddyzdrgrsu (gatcxmrhef, owdzbgeuue - tupdmvpuzl) View more | - | 13 Jan 2020 | ||
Placebo (Placebo) | mpiqhislad(ssvzvsgqfo) = tkzikinwcg ddyzdrgrsu (gatcxmrhef, xzyzutzqqa - ljucmrgpbu) View more | ||||||
Phase 3 | 201 | (HMPL-004 2400 mg/Day) | gulnzdiytj(sauhknnetc) = gsszwmuwno ztnmtwrdge (sdffjthggz, haoyrxqfsu - kludmyztje) View more | - | 02 Jan 2020 | ||
(HMPL-004 1800 mg/Day) | gulnzdiytj(sauhknnetc) = locqheqvhf ztnmtwrdge (sdffjthggz, rvbgmhreut - pvaartgfvq) View more | ||||||
Phase 2 | 101 | (HMPL-004) | zgknzgetay(jadjzyudvd) = bxkzcgvqpq ffdxnnjubj (iihcwvegmm, hvmvneznns - vfpmtxgqgx) View more | - | 03 Dec 2012 | ||
Placebo (Placebo) | zgknzgetay(jadjzyudvd) = ssrlxyivke ffdxnnjubj (iihcwvegmm, vbubrjpxpj - ffhxmxgzrp) View more |